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REGULAR ARTICLE
Graft-versus-host disease in recipients of male unrelated donor compared
with parous female sibling donor transplants
Anita J. Kumar,1 Soyoung Kim,2,3 Michael T. Hemmer,2 Mukta Arora,4 Stephen R. Spellman,5 Joseph A. Pidala,6 Daniel R. Couriel,7
Amin M. Alousi,8 Mahmoud D. Aljurf,9 Jean-Yves Cahn,10 Mitchell S. Cairo,11 Corey S. Cutler,12 Shatha Farhan,13 Usama Gergis,14
Gregory A. Hale,15 Shahrukh K. Hashmi,16 Yoshihiro Inamoto,17 Rammurti T. Kamble,18 Mohamed A. Kharfan-Dabaja,6
Margaret L. MacMillan,19 David I. Marks,20 Hideki Nakasone,21 Maxim Norkin,22 Muna Qayed,23 Olle Ringden,24 Harry C. Schouten,25
Kirk R. Schultz,26 Melhem M. Solh,27 Takanori Teshima,28 Alvaro Urbano-Ispizua,29 Leo F. Verdonck,30 Robert Peter Gale,31
Betty K. Hamilton,32 Navneet S. Majhail,32 and Alison W. Loren33
1Tufts Medical Center, Boston, MA; 2Center for International Blood and Marrow Transplant Research, Department of Medicine, and 3Institute for Health and Society,
Department of Biostatistics, Medical College of Wisconsin, Milwaukee, WI; 4Division of Hematology, Oncology and Transplantation, Department of Medicine, University of
Minnesota Medical Center, Minneapolis, MN; 5Center for International Blood and Marrow Transplant Research, National Marrow Donor Program/Be The Match,
Minneapolis, MN; 6Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; 7Utah Blood and Marrow
Transplant Program, Salt Lake City, UT; 8Department of Stem Cell Transplantation, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center,
Houston, TX; 9Department of Oncology, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia; 10Department of Hematology, Centre Hospitalier
Universitaire de Grenoble, Grenoble, France; 11Division of Pediatric Hematology, Oncology and Stem Cell Transplantation, Department of Pediatrics, New York Medical
College, Valhalla, NY; 12Center for Hematologic Oncology, Dana-Farber Cancer Institute, Boston, MA; 13Henry Ford Hospital Bone Marrow Transplant Program, Wayne
State University, Detroit, MI; 14Hematolgic Malignancies & Bone Marrow Transplant, Department of Medical Oncology, New York Presbyterian Hospital/Weill Cornell
Medical Center, New York, NY; 15Department of Hematology/Oncology, Johns Hopkins All Children’s Hospital, St. Petersburg, FL; 16Department of Internal Medicine,
Mayo Clinic, Rochester, MN; 17Fred Hutchinson Cancer Research Center, Seattle, WA; 18Division of Hematology and Oncology, Center for Cell and Gene Therapy,
Baylor College of Medicine, Houston, TX; 19University of Minnesota Blood and Marrow Transplant Program, Minneapolis, MN; 20Adult Bone Marrow Transplant, University
Hospitals Bristol National Health Service Trust, Bristol, United Kingdom; 21Jichi Medical University, Shimotsuke, Japan; 22Division of Hematology/Oncology, University
Florida College of Medicine, Gainesville, FL; 23Department of Pediatrics, Emory University School of Medicine, Atlanta, GA; 24Division of Therapeutic Immunology,
Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden; 25Department of Hematology, Academische Ziekenhuis, Maastricht, The Netherlands;
26Department of Pediatric Hematology, Oncology and Bone Marrow Transplant, British Columbia’s Children’s Hospital, The University of British Columbia, Vancouver,
BC, Canada; 27The Blood and Marrow Transplant Group of Georgia, Northside Hospital, Atlanta, GA; 28Kyushu University Hospital, Sapporo, Japan; 29Department of
Hematology, Hospital Clinic, University of Barcelona, Institut d’investigacions Biomediques August Pi i Sunyer, and Institute of Research Josep Carreras, Barcelona,
Spain; 30Department of Hematology/Oncology, Isala Clinic, Zwolle, The Netherlands; 31Hematology Research Centre, Division of Experimental Medicine, Department of
Medicine, Imperial College London, London, United Kingdom; 32Blood & Marrow Transplant Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; and
33Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
Key Points
•Compared with parous
female sibling donors,
male URDs confer
more aGVHD in all
patients and more
cGVHD in females.
• There was no difference
in survival, relapse, or
transplant mortality
between recipients of
parous female sibling
or male URD grafts.
Optimal donor selection is critical for successful allogeneic hematopoietic cell trans-
plantation (HCT). Donor sex and parity are well-established risk factors for graft-versus-
host disease (GVHD), with male donors typically associated with lower rates of GVHD.
Well-matched unrelated donors (URDs) have also been associatedwith increased risks of
GVHD as compared with matched sibling donors. These observations raise the question
of whether male URDs would lead to more (or less) favorable transplant outcomes as
comparedwith parous female sibling donors.Weused the Center for International Blood
and Marrow Transplant Research registry to complete a retrospective cohort study in
adults with acute myeloid leukemia, acute lymphoblastic leukemia, or myelodysplastic
syndrome, who underwent T-cell replete HCT from these 2 donor types (parous female
sibling or male URD) between 2000 and 2012. Primary outcomes included grade 2 to 4
acute GVHD (aGVHD), chronic GVHD (cGVHD), and overall survival. Secondary
outcomes included disease-free survival, transplant-related mortality, and relapse. In
2813 recipients, patients receivingmale URD transplants (n5 1921) had 1.6 times higher
risk of grade 2 to 4 aGVHD (P , .0001). For cGVHD, recipient sex was a significant
Submitted 16 October 2017; accepted 26 March 2018. DOI 10.1182/
bloodadvances.2017013052.
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factor, so donor/recipient pairs were evaluated. Female recipients of male URD grafts
had a higher risk of cGVHD than those receiving parous female sibling grafts (relative
risk [RR] 5 1.43, P , .0001), whereas male recipients had similar rates of cGVHD
regardless of donor type (RR 5 1.09, P 5 .23). Donor type did not significantly affect any
other end point. We conclude that when available, parous female siblings are preferred
over male URDs.
Introduction
Allogeneic hematopoietic cell transplant (HCT) is a potentially
curative but risky therapy for patients with hematologic malignancies.
Acute and chronic graft-versus-host disease (aGVHD and cGVHD,
respectively) are significant contributors to adverse outcomes
including death. To reduce complications from HCT, optimal donor
selection is critical. Specific factors influencing donor selection
include HLA matching, cytomegalovirus (CMV) serologic status,
ABO compatibility, age, sex, and parity (ie, the number of prior
pregnancies).1-3With increasing use of unrelated donors (URDs) for
allogeneic HCT, large studies have evaluated outcomes for patients
with sibling donor vs URD, with most demonstrating similar long-
term survival among the 2 donor groups.4-14 However, when given
the option of a sibling donor or URD, sibling donors are typically
preferred for convenience and possibly to reduce GVHD and to
improve survival. Both donor-recipient sex mismatching and the
effect of donor parity have been evaluated as possible influences on
transplant morbidity and mortality. There is an increased risk of
cGVHD (and in some studies, aGVHD) in recipients of grafts from
female donors, regardless of recipient sex, although some studies
indicate an even greater risk in male recipients, presumably because
of female donors’ immune response to the H-Y antigen.2,3,15-23
Female donors who have a history of pregnancy (“parous females”),
may confer more GVHD in all patients2,19,21 or, in some studies, only
in male recipients.3,15,16,18,23 In 2006, a large registry analysis using
the Center for International Blood and Marrow Transplant Research
(CIBMTR) evaluated the impact of sex and parity on aGVHD and
cGVHD after HLA-identical sibling HCT. This study established
parity as a risk factor for cGVHD in both male and female recipients
from parous female (vs male) sibling donors. It also demonstrated
that nulliparous female sibling donors confer an increased risk of
cGVHD to male recipients.21
Cost and delay are important considerations when choosing a
donor, and often transplant physicians choose sibling donors
regardless of sex or parity because of these concerns. However,
all patients who may be transplant candidates are now urged to
have HLA typing performed and siblings typed as early as
possible in the treatment course. Hence, we anticipate that
delays may become shorter or less frequently encountered when
using URDs. Furthermore, we hypothesized that if it were shown
that recipients of male URD grafts had substantially better
outcomes, a clinician may decide that some additional cost and/
or delay might be worthwhile. Given the well-documented
increased risk of aGVHD and cGVHD associated with parous
female sibling donors, we sought to understand whether
choosing a male URD would be a preferred strategy for donor
selection.
Methods
Data source
The data source for the study was the registry of the CIBMTR, a
collaboration between the National Marrow Donor Program and the
Medical College of Wisconsin: a voluntary working group of .500
transplantation centers that collaborates to share patient data and
conduct scientific studies. The quality and compliance of data
submission are monitored by computerized checks for errors,
physician reviews, and on-site audits. Observational studies
conducted by CIBMTR are performed with informed consent in
accordance with the Declaration of Helsinki and in compliance with
Health Insurance Portability and Accountability Act regulations as
determined by the National Marrow Donor Program and Medical
College of Wisconsin Institutional review board.
Patient selection
Adult patients who reported to theCIBMTRwith acutemyeloid leukemia
(AML), acute lymphoblastic leukemia (ALL), and myelodysplastic
syndrome (MDS) and who underwent a T-cell replete myeloablative,
nonmyeloablative, or reduced intensity conditioning HCT from an HLA-
identical parous female sibling or matched male URD between 2000
and 2012were included in the study. URDHLAmatchwas defined as a
high-resolution match at HLA-A, B, C, and DRB1 as previously
described.24 Donor parity was captured on CIBMTR collection forms
prior to HCT. Patients were at least 25 years old at the time of transplant
to allow a greater likelihood that sibling donors had the opportunity to be
parous and to reduce the likelihood of missing parity status in donors of
younger ages. Recipients of both peripheral blood stem cell (PBSC) and
bone marrow (BM) grafts were included.
Study design and end points
This was a retrospective cohort study examining outcomes among
patients who received HCTs from parous female sibling donors
compared with male URDs. The primary outcomes were incidence
of grade 2 to 4 aGVHD, cGVHD, and overall survival (OS). aGVHD
was present if graded 2 to 4 by cumulative incidence reported at 30,
60, and 100 days after transplantation.25 cGVHD was reported
as cumulative incidence at 6 months, 1 year, and 2 years after
transplantation.26,27 The competing risk for aGVHD and cGVHD was
death without GVHD. Patients were censored at date of subsequent
transplant or date of last follow-up. OS was defined as time to death
from any cause, with censoring at last follow-up.
Secondary end points included disease-free survival (DFS), transplant-
related mortality (TRM), and relapse. DFS was defined as time to
treatment failure (death or relapse). TRM was defined as any death
within 28 days after transplantation or death in continuous remission,
analyzed with relapse as a competing risk. Relapse was reported as
cumulative incidence with TRM as a competing risk.
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Statistical analysis
Univariable analysis. Donor, recipient, disease, and transplant-
related factors were compared between parous female sibling
and male URDs using the x2 test for categorical variables,
and the Wilcoxon rank-sum test for continuous variables, with
statistical significance set at P , .01 because of multiple
comparisons. OS and DFS were estimated using the Kaplan-Meier
method. Incidence of aGVHD, cGVHD, TRM, and relapse were
estimated using cumulative incidence models with competing risks.
Variables included the main effect of donor type (parous female
sibling vs male URD), as well as other donor-related variables (age,
ABO match, CMV serology). Additional variables included those
that were patient related (age, sex, race, Karnofsky performance
status); disease-related (disease type, disease stage at time of
transplant); and transplant-related (time from diagnosis to trans-
plant, graft source, conditioning regimen, GVHD prophylaxis, year
of transplant). Disease stage was defined as early (first complete
remission for AML and ALL; refractory anemia [RA] or RA with
ringed sideroblasts or pretransplant BM blasts ,5% for MDS),
intermediate (second or greater complete remission for AML and
ALL), or advanced (relapsed, primary refractory disease for AML
and ALL; RA with excess blasts, or BM blasts $5% for MDS).
There were no interactions between donor type and any
covariables.
Multivariable analysis. Multivariable Cox proportional haz-
ards regression was used to control for potentially confounding
clinical variables. Each variable was tested for the proportional
hazard assumption. If the assumption was violated, the variable
was included as a time-dependent variable. We assessed the
significance of donor type (parous female sibling and male URD)
on aGVHD, cGVHD, OS, DFS, TRM, and relapse by forcing this
variable into the models. To identify significant risk factors,
stepwise forward selection with a threshold of P 5 .01 was used
for entry and retention in the model. Interactions were tested
between the donor type and other significant covariables, and no
interactions were identified. SAS version 9.4 (SAS Institute, Cary,
NC) was used for the analyses.
Results
Patient characteristics
We identified 2813 patients in the CIBMTR registry who met the
inclusion criteria and had complete information on donor sex and
parity (parous female sibling donor 5 892, male URD 5 1921).
Race categories are reported to the CIBMTR as white, African
American, Asian/Pacific Islander, other, or missing. There were
small numbers of African American (2%), Asian/Pacific-Islander
(4%), and other/missing (4%), so these were pooled into a single,
nonwhite group. All male URDs were high-resolution matched at
HLA-A, B, C, and DRB1, and the majority were also matched at
HLA-DQB1 (89%), but mismatched for HLA-DPB1 (64%).
There was no difference in median age between the 2 recipient
cohorts, although a smaller proportion of parous female sibling
recipients were.60 years (14% vs 21%). Donor age was higher in
the parous female sibling group (48 vs 32 years, P , .001). There
were significantly more PBSC grafts in the parous female sibling
group (87% vs 76%, P , .001). A majority of patients were
transplanted with early stage disease. The median time from
diagnosis to transplant differed between the 2 groups (parous
female sibling: 5 months, male URD: 7 months; P , .001). Median
follow-up of survivors was 66 months (range 3-170) for parous
female sibling recipients and 72 months (range 3-169) for male
URD recipients, P , .001 (Tables 1-3).
aGVHD
There was an increased risk of grade 2 to 4 aGVHD in recipients
of male URD grafts as compared with recipients of parous female
sibling donor grafts (100-day grade 2-4 aGVHD 46% in patients
receiving male URD grafts vs 35% in those receiving parous
female sibling grafts). This finding persisted in multivariable
analysis (relative risk [RR] 5 1.56, P , .0001) (Figure 1). Other
significant covariables associated with grade 2 to 4 aGVHD
included GVHD prophylaxis (tacrolimus/methotrexate lowest
risk, P 5 .0019) and graft source (PBSC higher risk, RR 5 1.32,
P5 .0003). Recipients of parous female sibling donor grafts may also
have experienced a higher risk of grade 3 to 4 aGVHD as compared
with recipients of male URD grafts, but this finding did not reach
statistical significance given our conservative P value cutoff
(RR 5 1.27, P 5 .016) (Table 4).
Table 1. Recipient characteristics
Variable Parous sibling Male URD P
Number of patients 892 1921
Age at transplant, median (range), y 49 (25-76) 50 (25-75) .15
Age at transplant, n (%), y ,.001
25-39 202 (23) 484 (25)
40-49 264 (30) 464 (24)
50-59 297 (33) 566 (29)
$60 129 (14) 407 (21)
Sex, n (%) .07
Male 481 (54) 1107 (58)
Female 411 (46) 814 (42)
Race, n (%) ,.001
White 742 (83) 1795 (93)
Nonwhite 131 (15) 98 (5)
Missing 19 (2) 28 (1)
Karnofsky score prior to HCT (%) .73
,90% 304 (34) 631 (33)
$90% 563 (63) 1138 (59)
Missing 25 (3) 152 (8)
Disease, n (%) .94
AML 553 (62) 1184 (62)
ALL 160 (18) 341 (18)
MDS 179 (20) 396 (21)
Disease status at HCT, n (%) ,.001
Early 540 (60) 1000 (52)
Intermediate 116 (13) 357 (19)
Advanced 228 (26) 553 (29)
Missing 8 (,1) 11 (,1)
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cGVHD
At 6 months and 1 year posttransplantation, there was no difference
in incidence of cGVHD among male URD recipients (33% and
50%, respectively) as compared with parous female sibling
recipients (30% and 50%, respectively). We found that recipient
sex was a significant covariable in the cGVHD multivariable model,
so this model was adjusted to include a combination of donor
type and recipient sex as the main effect. For male recipients,
the risk of cGVHD was similar between donor types (34% for
each donor type, P 5 .89 at 6 months, and 55% for parous
female sibling donor vs 51% for male URDs, P 5 .09 at 12
months; RR 5 1.09, P 5 .23). However, female recipients
receiving male URD grafts experienced higher risks of cGVHD
at 6 months posttransplant (31% as compared with 24% in
female recipients receiving parous female sibling donor grafts,
P5 .01). By 1 year posttransplant, this difference was no longer
statistically significant (50% of females receiving male URD
grafts experienced cGVHD as compared with 44% of females
receiving parous female sibling grafts, P 5 .07). In multivariable
analysis, for female patients, male URDs conferred an adjusted
relative risk of cGVHD of 1.43 (P , .0001) compared with
those receiving parous female sibling grafts. Other significant
covariables included year of transplant, with cGVHD more
frequently seen in earlier transplant years (overall P 5 .002),
and receipt of peripheral blood grafts (RR 5 1.73 compared
with BM, P , .0001) (Table 4). In male patients, donor type did
not significantly impact cGVHD (Figure 2).
OS
A smaller percentage of male URD recipients were alive at 100 days
(82% vs 88% of recipients of parous female sibling transplants,
P, .001). However, by 1 year, this difference disappeared (Figure 3).
Table 2. Donor characteristics
Variable Parous sibling Male URD P
Donor age, median (range), y 48 (3-82) 32 (18-61) ,.001
Donor age, n (%), y ,.001
18-19 1 (,1) 52 (3)
20-29 35 (4) 750 (39)
30-39 180 (20) 651 (34)
40-49 284 (32) 380 (20)
50-59 252 (28) 83 (4)
$60 136 (15) 2 (,1)
Missing 4 (,1) 3 (,1)
D/R CMV serologic status, n (%) ,.001
2/2 149 (17) 605 (31)
2/1 157 (18) 713 (37)
1/2 122 (14) 158 (8)
1/1 439 (49) 365 (19)
Missing 25 (3) 80 (4)
D/R ABO match, n (%) ,.001
Matched 580 (65) 859 (45)
Minor mismatch 128 (14) 459 (24)
Major mismatch 135 (15) 450 (23)
Bidirectional mismatch 40 (4) 147 (8)
Missing 9 (1) 6 (,1)
Number of prior pregnancies in female donors, n (%) N/A
1 137 (15) 0
2 277 (31) 0
3 185 (21) 0
$4 175 (20) 0
Missing 118 (13) 0
D/R, donor/recipient; N/A, not applicable.
Table 3. HCT characteristics
Variable Parous sibling Male URD P
Time from diagnosis to transplant,
median (range), mo
5 (,1-153) 7 (,1-291) ,.001
Time from diagnosis to transplant, n (%), mo ,.001
,6 492 (55) 821 (43)
6-12 197 (22) 522 (27)
.12 203 (23) 574 (30)
Missing 0 4 (,1)
Graft type, n (%) ,.001
BM 118 (13) 462 (24)
Peripheral blood 774 (87) 1459 (76)
Conditioning regimen intensity, n (%) .38
Myeloablative 673 (75) 1403 (73)
TBI 341 (51) 685 (49)
No TBI 332 (49) 718 (51)
Reduced intensity 165 (18) 385 (20)
TBI 31 (19) 67 (17)
No TBI 134 (81) 318 (83)
Nonmyeloablative 54 (6) 133 (7)
TBI 51 (95) 122 (92)
No TBI 3 (5) 11 (8)
GVHD prophylaxis, n (%) ,.001
Tac 1 MTX 266 (30) 834 (43)
Tac 1 MTX 1 others 29 (3) 176 (9)
Tac 6 others 121 (14) 365 (19)
CsA 1 MTX 310 (35) 278 (14)
CsA 6 others 128 (14) 191 (10)
Others* 36 (4) 76 (4)
Missing 2 (,1) 1 (,1)
Year of transplant, n (%) ,.001
2000-2003 255 (29) 317 (17)
2004-2008 375 (42) 1119 (58)
2009-2012 262 (29) 485 (25)
CsA, cyclosporine; MMF, mycophenolate mofetil; MTX, methotrexate; Tac, tacrolimus;
TBI, total body irradiation.
*Tac 1 CsA 1 MTX (n 5 32), posttransplant cyclophosphamide (n 5 25), Tac 1 CsA 1
MTX 1 MMF (n 5 13), Tac 1 CsA 1 MMF (n 5 12), Tac 1 CsA 1 MTX 1 others (n 5 6),
Tac 1 CsA 1 MMF 1 others (n 5 2), Tac 1 CsA 1 others (n 5 7), MTX 1 others (n 5 5),
MTX (n 5 2), MMF (n 5 3), MMF 1 others (n 5 3), Siro (n 5 1), steroids (n 5 1).
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In multivariable analysis, this small decrement in OS in recipients of
male URD donor grafts persisted, although it no longer reached
statistical significance (male URD RR 5 1.10; 99% CI, 0.99-1.26;
P 5 .07). Other variables associated with poorer OS included older
age, poorer Karnofsky score, advanced disease status at transplant,
and earlier year of transplant (Table 5). Cause of death was largely
because of primary disease and was similar between the 2 groups
(parous female sibling 41%, male URD 44%). Six percent of deaths
in both the parous female sibling and male URD groups were
attributable to aGVHD. A comparable incidence of death attributed to
cGVHD was seen in the 2 groups.
Secondary end points
DFS. DFS was inferior in the male URD cohort at 100 days
(male URD 73% vs parous female sibling 78%, P 5 .003) and at
6 months (60% vs 65%, respectively, P 5 .008) posttransplan-
tation. At 1 year and beyond, however, there was no significant
difference in DFS: 1-year male URD 49% vs parous female sibling
54% (P5 .03), 2-year male URD 41% vs parous female sibling 44%
(P 5 .19), 3-year male URD 37% vs parous female sibling 39%
(P5 .49), and 5-year male URD 33% vs parous sibling 34% (P5 .52).
In multivariable analysis, donor type was not associated with DFS
(P 5 .449). Older patient age, poorer Karnofsky score, TBI-based
conditioning, advanced disease, longer time from diagnosis to
aGVHD, Grades II-IV by Donor Group
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Figure 1. Cumulative incidence of grade 2 to 4 aGVHD by donor type.
Table 4. GVHD outcomes
aGVHD 2-4 aGVHD 3-4
aGVHD variable n RR 99% CI P n RR 99% CI P
Donor group (main effect)
Parous sibling 880 1.00 880 1.00
Male unrelated 1908 1.56 1.31-1.85 ,.0001 1908 1.27 0.98-1.64 .016
GVHD prophylaxis .002 .0002
Tac 1 MTX 1094 1.00 1094 1.00
Tac 1 MTX 1 others 202 1.12 0.65-1.18 .258 202 1.12 0.72-1.74 .502
Tac 6 others 480 1.11 0.84-1.28 .632 480 1.11 0.80-1.53 .410
CsA 1 MTX 583 0.92 0.80-1.23 .960 583 0.92 0.66-1.28 .500
CsA 6 others 315 1.75 1.09-1.72 .0001 315 1.75 1.26-2.43 ,.0001
Others 112 1.20 0.91-1.86 .062 112 1.20 0.69-2.10 .389
Graft source
BM 578 1.00 – – – –
PB 2213 1.32 1.08-1.61 .0003 – – – –
All donor/recipient pairs Male recipients only
cGVHD variable n RR 99% CI P n RR 99% CI P
Donor/recipient pair (main effect) ,.0001
Parous sibling to female 405 1.00
Parous sibling to male 474 1.39 1.09-1.78 .001 474 1.00
Male unrelated to female 799 1.43 1.14-1.80 ,.0001
Male unrelated to male 1099 1.52 1.22-1.89 ,.0001 1099 1.09 0.90-1.32 .231
Year of transplant .002 ns
2000-2003 564 1.00
2004-2008 1471 1.06 0.88-1.29 .381
2009-2012 742 0.86 0.70-1.06 .064
Graft source
BM 574 1 327 1.00
PB 2203 1.73 1.43-2.08 ,.0001 1246 1.56 1.23-2.08 ,.0001
CI, confidence interval; parous sibling, parous sibling donor; PB, peripheral blood; ns, not significant.
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transplant, and earlier year of transplant were associated with
poorer DFS (Table 6).
Relapse. There was no significant difference in incidence
of relapse between the 2 donor cohorts at any time post-
transplantation (P 5 .59). The increased risk of GVHD was not
offset by lower relapse rate: in multivariable analysis, the relative
risk of relapse in male URD recipients was 1.03 (P 5 .61).
Significant variables associated with relapse included older age
of the patient, AML diagnosis (vs MDS), and advanced disease
status (Table 6).
TRM. TRM was greater in recipients of male URD grafts at
100 days (11% vs 8%, P 5 .003). However, at 6 months and
beyond, incidence of TRM was not significantly different between
the 2 cohorts. In multivariable analysis, donor type was not
significantly predictive of TRM, but older age, poorer Karnofsky
score, TBI-based conditioning, and earlier year of transplant were
associated with higher TRM (Table 6).
Discussion
We undertook this analysis to provide guidance to transplant
clinicians when the only available sibling donor is a sister with
previous pregnancies, as these donors are known to confer an
increased risk of aGVHD and cGVHD when compared with male
siblings. We sought to answer the question, would unrelated male
donors be preferable to parous female siblings?We found that after
adjusting for other significant covariables, recipients of male URD
grafts experienced a 56% higher risk of grade 2 to 4 aGVHD
compared with recipients of parous female sibling grafts. Although
parous female siblings more frequently donated PBSC, a
product known to increase cGVHD, the effect was preserved
even when controlling for this variable.28 When evaluating only
the most severe aGVHD (grade 3 to 4) this increased risk may
have persisted, but our results no longer demonstrated statistical
significance, possibly because of a relatively low incidence of
severe aGVHD in the study sample. The increased early TRM in
the male URD group may be attributable in part to the higher
incidence of aGVHD. However, over time, TRM and OS were not
significantly impacted by donor source in our multivariable
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Figure 3. OS survival by donor type.
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Figure 2. Cumulative incidence of cGVHD by donor type and recipient sex.
(A) Male recipients. (B) Female recipients.
Table 5. Cox regression for OS
Variable N HR 99% CI P
Donor group (main effect)
Parous sibling 892 1.00
Male unrelated 1921 1.10 0.96-1.26 .070
Age at transplant, y ,.0001
25-39 (ref) 686 1.00
40-49 728 1.20 1.00-1.43 .010
50-59 863 1.43 1.21-1.70 ,.0001
601 536 1.61 1.33-1.95 ,.0001
Karnofsky score at transplant ,.0001
$90 (ref) 1701 1.00
,90 935 1.36 1.20-1.55 ,.0001
Missing 177 1.03 0.81-1.33 .724
Disease status at transplant ,.0001
Early (ref) 1540 1.00
Intermediate 473 1.11 0.93-1.32 .119
Advanced 781 1.82 1.59-2.08 ,.0001
Missing 19 1.90 0.99-3.66 .011
Year of transplant ,.0001
2000-2003 (ref) 572 1.00
2004-2008 1494 0.96 0.82-1.13 .523
2009-2012 747 0.76 0.63-0.92 ,.001
HR, hazard ratio; ref, reference value.
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analyses, suggesting that the impact of aGVHD on these
outcomes occurs early posttransplantation and may be counter-
balanced by other factors posttransplant.
In contrast to aGVHD, the incidence of cGVHD varied not just by
donor type, but also by sex of the recipient. We found that male
recipients had equivalent rates of cGVHD regardless of donor type,
whereas female recipients fared better with parous female sibling
donors. Although prior work has focused on cGVHD in male
recipients of female donor grafts, as female T cells recognize
Y-chromosome encoded male-specific minor histocompatibility (H-Y)
antigens,29,30 this study suggests that other minor histocompatibility
antigen mismatches may bemore important than H-Y mismatch.Why
this effect was seen only in female recipients is unclear.
OS did not appear to be better among recipients of male URD
grafts, possibly because TRM from cGVHD may have offset other
benefits. Although some prior studies in URDs have found no
association between parity and OS,24 others have demonstrated
poorer OS (and higher TRM) in male recipients of female grafts,31
and yet other analyses have shown improved OS.32 It is difficult to
reconcile the marked differences in survival outcomes in the many
studies that have evaluated donor sex or parity, but our large study
suggests that if parity is a risk factor for GVHD or other poor
outcomes, it is not as significant as the effects of receiving a graft
from a URD. Like most transplant analyses, we confirmed that older
patient age, poorer patient performance status, advanced disease,
and earlier year of transplant were associated with poorer OS.2
Table 6. Multivariable analyses for DFS, TRM, and relapse
DFS TRM Relapse
Variable N RR 99% CI P RR 99% CI P RR 99% CI P
Donor group (main effect)
Parous sibling (ref) 852 1.00 1.00 1.00
Male URD 1901 1.04 0.91-1.19 .449 1.07 0.88-1.31 .380 1.03 0.87-1.23 .610
Age at transplant, y ,.0001 ,.0001 ,.0001
25-39 (ref) 669 1.00 1.00 1.00
40-49 710 1.17 0.98-1.40 .022 1.32 1.01-1.74 .009 1.09 0.86-1.37 .360
50-59 848 1.39 1.170-1.64 ,.0001 1.67 1.29-2.17 ,.0001 1.27 1.02-1.58 .006
601 526 1.66 1.37-2.00 ,.0001 2.05 1.53-2.75 ,.0001 1.53 1.19-1.96 ,.0001
Disease ,.0001
AML (ref) 1701 – – – – – – 1.00
ALL 490 – – – – – – 0.97 0.77-1.21 .708
MDS 562 – – – – – – 0.62 0.49-0.77 ,.0001
Karnofsky score at transplant ,.0001
$90 (ref) 1662 1.00 1.00 – – –
,90 917 1.31 1.15-1.48 ,.0001 1.59 1.31-1.92 ,.0001 – – –
Missing 174 1.10 0.86-1.41 .308 1.11 0.75-1.63 .487 – – –
TBI used in conditioning regimen
TBI 6 others (ref) 1277 1.00 1.00 – – –
Non-TBI 1476 0.86 0.76-0.97 .002 0.83 0.69-0.99 .008 – – –
Disease status at transplant ,.0001 ,.0001
Early (ref) 1509 1.00 – – – 1.00
Intermediate 466 1.06 0.890-1.26 .407 – – – 1.12 0.89-1.42 .198
Advanced 760 1.87 1.63-2.14 ,.0001 – – – 2.57 2.15-3.06 ,.0001
Missing 18 1.81 0.92-3.56 .023 – – – 2.73 1.24-6.02 .001
Year of transplant .005 .002
2000-2003 (ref) 544 1.00 1.00 – – –
2004-2008 1464 0.96 0.82-1.13 .534 0.85 0.68-1.08 .077 – – –
2009-2012 745 0.82 0.68-0.98 .004 0.68 0.52-0.90 ,.001 – – –
Time from diagnosis to transplant, mo .0054
,6 (ref) 1286 – – – 1.00 – – –
6-12 702 – – – 1.35 1.08-1.68 .0004 – – –
.12 761 – – – 1.10 0.88-1.37 .2842 – – –
Missing 4 – – – 1.44 0.11-19 .7165 – – –
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We acknowledge limitations in our study. As with all registry studies,
there may be miscategorization of the incidence of GVHD. Although
we have information on degree of HLA match, this did not include
data on killer-cell immunoglobulin-like receptor (KIR) gene com-
plexes, which may affect early relapse and mortality.33 Furthermore,
we did not control for permissive and nonpermissive mismatching at
DQB1 and DP. We did not evaluate the use of donor leukocyte
infusions for relapsed disease in our analysis, which could impact
the incidence of aGVHD and cGVHD, as well as relapse and OS.
Our analysis was restricted to T-cell replete transplants, and hence
our findings may not be extrapolated to patients receiving in vivo or
ex vivo T-cell-depleted transplants. This is particularly relevant given
our primary end points of aGVHD and cGVHD.34,35 Finally, as in all
studies analyzing donor parity, we recognize that documentation
of parity may be unreliable and subject to misclassification bias.
However, if a nulliparous female donor were miscategorized as
parous, we expect that this would bias the results toward the null.
In conclusion, compared with parous female sibling donors, male
URDs imparted an increased risk of grade 2 to 4 aGVHD to all
recipients, an increased risk of cGVHD to female recipients, and an
equivalent risk of cGVHD to male recipients. This finding suggests
that other minor histocompatibility antigen mismatches outweigh
the impact of H-Y mismatch. Donor type does not impact long-term
OS. When faced with a choice of an unrelated male donor or a
parous female sibling donor, physicians should favor HLA-identical
sibling donors irrespective of donor sex and parity in order to reduce
the risk of aGVHD and cGVHD.
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